Plasma TNF-α and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic Index-Reference-Cited by-同舟云学术

Plasma TNF-α and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic Index

Published:2010-02-27 Issue:2 Volume:58 Page:131-141
ISSN:0004-069X
Container-title:Archivum Immunologiae et Therapiae Experimentalis
language:en
Short-container-title:Arch. Immunol. Ther. Exp.

Author:

Lech-Maranda Ewa,Bienvenu Jacques,Broussais-Guillaumot Florence,Warzocha Krzysztof,Michallet Anne-Sophie,Robak Tadeusz,Coiffier Bertrand,Salles Gilles

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00005-010-0066-1.pdf

Reference33 articles.

1. (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329:987–994

2. Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3:745–756

3. Alas S, Emmanouilides C, Bonavida B (2001) Inhibition of interleukin 10 by Rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clin Cancer Res 7:709–723

4. Benjamin D, Knobloch TJ, Dayton MA (1992) Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt’s lymphoma constitutively secrete large quantities of interleukin-10. Blood 80:1289–1298

5. Blay JY, Burdin N, Rousset F et al (1993) Serum interleukin-10 in non-Hodgkin’s lymphoma: a prognostic factor. Blood 82:2169–2174

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application;Molecular Cancer;2024-02-17

2. Cytokine profiles in patients with newly diagnosed diffuse large B-cell lymphoma: IL-6 and IL-10 levels are associated with adverse clinical features and poor outcomes;Cytokine;2023-09

3. Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment;CLIN CANCER RES;2023

4. Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment;Clinical Cancer Research;2023-06-26

5. HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma;Blood Advances;2023-03-02